

## **BONESUPPORT – Publication of pre-clinical study highlighting unique bone remodeling qualities of CERAMENT® in large bone defects**

Lund, Sweden, 08.00 CET, 08 February 2019 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, today announces the publication of groundbreaking data on bone remodeling of CERAMENT in pre-clinical model. The study ‘Establishment and effects of allograft and synthetic bone graft substitute treatment of a critical size metaphyseal bone defect model in the sheep femur’ is published in APMIS (*Acta Pathologica, Microbiologica et Immunologica Scandinavica*).

**BONESUPPORT EVP R&D, Medical & Clinical Affairs and senior author of the publication Dr Michael Diefenbeck commented:** “This pilot study represents an important initial step towards establishing a clinically relevant large animal model that allows thorough investigation of bone graft substitute-mediated bone defect regeneration, in-depth analysis of its interaction with host bone and accurate documentation of the resulting bone remodeling over time. The combination of different imaging methods like radiographs,  $\mu$ CT, MRI and histology provide a clearer insight into the healing process of the bone tissue. Histological evaluations helped to confirm the resorption of CERAMENT® and regeneration of trabecular bone in the periphery of the void as early as three months”.

BONESUPPORT performed the research in collaboration with authors from the Universities in Copenhagen, Munich and Jena; Dr Werner Hettwer, Dr Peter Horstmann, Dr Sabine Bischoff, Dr Daniel Güllmar, Prof Jürgen Reichenbach, Dr Patrina Su Ping Poh, Prof Martijn van Griensven and Dr Florian Gras.

The publication can be found in APMIS Journal of Pathology, Microbiology and Immunology: <https://onlinelibrary.wiley.com/doi/10.1111/apm.12918>

### **About BONESUPPORT™**

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 129 million in 2017. Please visit [www.bonesupport.com](http://www.bonesupport.com) for more information.

BONESUPPORT and CERAMENT are registered trademarks.

## Press Release

**For more information contact:**

**BONESUPPORT AB**

Emil Billbäck, CEO  
+46 (0) 46 286 53 70

Håkan Johansson, CFO  
+46(0) 46 286 53 70  
[ir@bonesupport.com](mailto:ir@bonesupport.com)

**Cord Communications**

Charlotte Stjerngren  
+46 (0)708 76 87 87  
[charlotte.stjerngren@cordcom.se](mailto:charlotte.stjerngren@cordcom.se)  
[www.cordcom.se](http://www.cordcom.se)